Abstract
Bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH) is a significant lung morbidity of infants, and disrupted lung angiogenesis is a hallmark of this disease. We observed that extracellular signal-regulated kinases (ERK) 1/2 support angiogenesis in vitro, and hyperoxia activates ERK1/2 in fetal human pulmonary microvascular endothelial cells (HPMECs) and in neonatal murine lungs; however, their role in experimental BPD and PH is unknown. Therefore, we hypothesized that Tie2 Cre-mediated deficiency of ERK2 in the endothelial cells of neonatal murine lungs would potentiate hyperoxia-induced BPD and PH. We initially determined the role of ERK2 in in vitro angiogenesis using fetal HPMECs. To disrupt endothelial ERK2 signaling in the lungs, we decreased ERK2 expression by breeding ERK2flox/flox mice with Tie-Cre mice. One-day-old endothelial ERK2-sufficient (eERK2+/+) or –deficient (eERK2+/−) mice were exposed to normoxia or hyperoxia (FiO2 70%) for 14 d. We then performed lung morphometry, gene and protein expression studies, and echocardiography to determine the extent of inflammation, oxidative stress, and development of lungs and PH. The knockdown of ERK2 in HPMECs decreased in vitro angiogenesis. Hyperoxia increased lung inflammation and oxidative stress, decreased lung angiogenesis and alveolarization, and induced PH in neonatal mice; however, these effects were augmented in the presence of Tie2-Cre mediated endothelial ERK2 deficiency. Therefore, we conclude that endothelial ERK2 signaling is necessary to mitigate hyperoxia-induced experimental BPD and PH in neonatal mice. Our results indicate that endothelial ERK2 is a potential therapeutic target for the management of BPD and PH in infants.
Highlights
Bronchopulmonary dysplasia (BPD) is a chronic lung disease of infants that results from interrupted lung development [1]
Our study indicates that the mitogen-activated protein (MAP) kinase, extracellular signal-regulated kinase (ERK) 2, is one such druggable target
We recently observed that hyperoxia exposure activates ERK2 more than ERK1 in fetal human lung endothelial cells [30]
Summary
Bronchopulmonary dysplasia (BPD) is a chronic lung disease of infants that results from interrupted lung development [1]. Understanding the molecular mechanisms that promote the development and function of the lung blood vessels is important to mitigate this human disease. To this end, the vascular endothelial growth factor (VEGF) and nitric oxide (NO) signaling pathways have been extensively investigated, and they have been shown to be necessary for lung development in health and disease in neonatal animals [12,13,14,15,16]. There is a need to identify additional druggable molecular targets that can complement inhaled NO therapy to promote the development and function of the lung vascular system. Our study indicates that the mitogen-activated protein (MAP) kinase, extracellular signal-regulated kinase (ERK) 2, is one such druggable target
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.